Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy.

Ishimori T, Saga T, Nagata Y, Nakamoto Y, Higashi T, Mamede M, Mukai T, Negoro Y, Aoki T, Hiraoka M, Konishi J.

Ann Nucl Med. 2004 Dec;18(8):669-74.

PMID:
15682847
2.

The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET.

Hsieh HJ, Lin SH, Lin KH, Lee CY, Chang CP, Wang SJ.

Ann Nucl Med. 2008 Jul;22(6):533-8. doi: 10.1007/s12149-007-0142-8. Epub 2008 Aug 1.

PMID:
18670862
3.
4.

Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.

Hashimoto Y, Tsujikawa T, Kondo C, Maki M, Momose M, Nagai A, Ohnuki T, Nishikawa T, Kusakabe K.

J Nucl Med. 2006 Mar;47(3):426-31.

5.

Impact of dual-time-point (18)F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules.

Alkhawaldeh K, Bural G, Kumar R, Alavi A.

Eur J Nucl Med Mol Imaging. 2008 Feb;35(2):246-52. Epub 2007 Oct 16.

PMID:
17938921
6.

Comparison of MET-PET and FDG-PET for differentiation between benign lesions and lung cancer in pneumoconiosis.

Kanegae K, Nakano I, Kimura K, Kaji H, Kuge Y, Shiga T, Zhao S, Okamoto S, Tamaki N.

Ann Nucl Med. 2007 Aug;21(6):331-7. Epub 2007 Aug 27.

PMID:
17705012
7.

Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT.

Christensen JA, Nathan MA, Mullan BP, Hartman TE, Swensen SJ, Lowe VJ.

AJR Am J Roentgenol. 2006 Nov;187(5):1361-7.

PMID:
17056930
8.

Clinical value of [¹¹C]methionine PET for stereotactic radiation therapy with intensity modulated radiation therapy to metastatic brain tumors.

Miwa K, Matsuo M, Shinoda J, Aki T, Yonezawa S, Ito T, Asano Y, Yamada M, Yokoyama K, Yamada J, Yano H, Iwama T.

Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1139-44. doi: 10.1016/j.ijrobp.2012.02.032. Epub 2012 Apr 18.

PMID:
22520479
9.

Assessing the usefulness of 18F-fluorodeoxyglucose PET-CT scan after stereotactic body radiotherapy for early-stage non-small cell lung cancer.

Pastis NJ Jr, Greer TJ, Tanner NT, Wahlquist AE, Gordon LL, Sharma AK, Koch NC, Silvestri GA.

Chest. 2014 Aug;146(2):406-11. doi: 10.1378/chest.13-2281.

10.

Quantitative evaluation of correlation of dose and FDG-PET uptake value with clinical chest wall complications in patients with lung cancer treated with stereotactic body radiation therapy.

Algan O, Confer M, Algan S, Matthiesen C, Herman T, Ahmad S, Ali I.

J Xray Sci Technol. 2015;23(6):727-36. doi: 10.3233/XST-150523.

PMID:
26756408
11.

Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.

Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, Bormans G, Mortelmans L.

Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):39-51. Epub 2004 Aug 10.

PMID:
15309329
12.

Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies.

Pirotte B, Goldman S, Massager N, David P, Wikler D, Lipszyc M, Salmon I, Brotchi J, Levivier M.

J Neurosurg. 2004 Sep;101(3):476-83.

PMID:
15352606
13.

Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas.

Pirotte B, Goldman S, Massager N, David P, Wikler D, Vandesteene A, Salmon I, Brotchi J, Levivier M.

J Nucl Med. 2004 Aug;45(8):1293-8.

14.
15.

Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.

Hellwig D, Gröschel A, Graeter TP, Hellwig AP, Nestle U, Schäfers HJ, Sybrecht GW, Kirsch CM.

Eur J Nucl Med Mol Imaging. 2006 Jan;33(1):13-21. Epub 2005 Sep 9.

PMID:
16151765
16.

Dual time point 18F-FDG PET for the evaluation of pulmonary nodules.

Matthies A, Hickeson M, Cuchiara A, Alavi A.

J Nucl Med. 2002 Jul;43(7):871-5.

17.
18.

11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET.

Kim S, Chung JK, Im SH, Jeong JM, Lee DS, Kim DG, Jung HW, Lee MC.

Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):52-9. Epub 2004 Aug 10.

PMID:
15309332
19.

[11C] methionine and [18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme.

Pötzi C, Becherer A, Marosi C, Karanikas G, Szabo M, Dudczak R, Kletter K, Asenbaum S.

J Neurooncol. 2007 Sep;84(3):305-14. Epub 2007 May 11.

PMID:
17492401
20.

Comparison of MET-PET and FDG-PET for differentiation between benign lesions and malignant tumors of the lung.

Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Koga H, Hayashi K, Kaneko K, Chen T, Ichiya Y, Masuda K.

Ann Nucl Med. 2001 Oct;15(5):425-31.

PMID:
11758947

Supplemental Content

Support Center